デラウェア州における非小細胞肺癌の臨床試験
デラウェア州内の拠点で、非小細胞肺癌に関する21件の研究が参加者を募集しています。
デラウェア州内の都市
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Medical Oncology Hematology Consultants, Newark
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07388524Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Medical Oncology Hematology Consultants, PA, Newark
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361497A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Medical Oncology Hematology Consultants, PA, Newark
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07144280A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- ChristianaCare Health System, Newark
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07154290A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Newark
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06868277Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Bayhealth Cancer Center- Kent, Dover
- Bayhealth Cancer Center- Sussex, Milford
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/22更新 · NCT07028489An External Control Arm Study in Non-Small Cell Lung Cancer
- Bayhealth Medical Center, Kent Campus, Dover
- Bayhealth Medical Center- Sussex Campus, Milford
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174388A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Medical Oncology Hematology Consultants, PA, Newark
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06875310A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Newark
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06692738Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Newark
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07291037Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
被験者募集中第2相
18歳以上 · 全性別 · 2026/06/03更新 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
被験者募集中第2相
18 Minutes · 全性別 · 2026/05/05更新 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/05/05更新 · NCT06616584Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 他1件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Newark
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。